Today marks the start of the phase 3 trial of Moderna's COVID-19 vaccine candidate. The COVE trial (Coronavirus Efficacy) will enroll 30,000 people at 89 sites across the country, with half the recipients receiving two shots of the vaccine 28 days apart, and the other half receiving placebos.
The study is blinded.According to Moderna, the primary endpoint will be the prevention of symptomatic COVID-19 disease, and secondary endpoints will include prevention of severe COVID-19 disease (as defined by the need for hospitalization) and prevention of infection by SARS-CoV-2, the virus that causes COVID-19, regardless of symptoms.